Peter Barany

Peter Barany

Affiliated to Research | Docent
Visiting address: Baxter Novum, Hälsovägen 7, plan 5, 14186 Stockholm
Postal address: H9 Klinisk vetenskap, intervention och teknik, H9 CLINTEC Med njursjukdomar, 141 52 Huddinge
Part of:

Articles

All other publications

Grants

  • Swedish Research Council
    1 January 2022 - 31 December 2025
    Atrial fibrillation (AF) is a frequent cardiovascular complication in people with chronic kidney disease (CKD), which more than double the risk of stroke. Currently there is a knowledge gap in the efficacy and safety of all anticoagulant treatments in people with CKD stage 5 (glomerular filtration rate &lt
    15 ml/min/1.73m2 and dialysis). Warfarin has unknown efficacy and increase the risk of bleeding and calcifylaxis. The trials of direct oral anticoagulants (DOAC) excluded patients with creatinine clearance&lt
    25 ml/min/1.73m2. Stroke prophylaxis with Apixaban in CKD 5 patients with atrial fibrillation (SACK), is a pragmatic, prospective, open label, registry-randomized controlled trial in Sweden, Norway, Finland, and Iceland where we will randomize patients with CKD stage 5 and AF to treatment with apixaban (DOAC) 2.5 mg x 2 or no treatment. Our primary objective is to evaluate if treatment with apixaban reduces the risk of ischemic stroke without causing an unacceptable increase in the risk of intracranial bleeding and fatal bleeding. Our secondary objective is to evaluate the risk of all major bleedings, and all-cause mortality. The patients will be followed for a minimum of three years and the results are estimated by 2028. The results from SACK will contribute important evidence in a population systematically excluded from clinical trials of stroke prophylaxis in AF.
  • Swedish Research Council
    1 January 2019 - 31 December 2019

Employments

  • Affiliated to Research, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 2024-2027

Degrees and Education

  • Docent, karolinska institutet, 2008

Supervision

  • 0

    • 1

      • 2

        News from KI

        Events from KI